Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-07
2005-06-07
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S254100, C514S255030, C514S317000, C514S326000, C544S392000, C544S393000, C544S395000, C546S214000, C546S230000, C546S232000, C546S233000, C546S236000, C546S237000
Reexamination Certificate
active
06903120
ABSTRACT:
New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1), wherein X N, CH, or C, however X may only be C when the compound comprises a double bond at the dotted line; R1is OSO2CF3, OSO2CH3, SOR3, SO2R3, COR3, NO2, or CONHR3and when X is CH or C R1may also be CF3, CN, F, Cl, Br, or I; R2is a C1-C4alkyl, an allyl, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl, 4,4,4,-trifluorobutyl, or —(CH2)—R4; R3is a C1-C3alkyl CF3, or N(R2)2; R4is a C3-C6cycloalkyl, 2-tetrahydrofurane or 3-tetra-hydrofurane, as well as pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed
REFERENCES:
patent: 3326916 (1967-06-01), Creighton
patent: 4202898 (1980-05-01), Depoortere
patent: 0 060 179 (1982-02-01), None
patent: 0 369 887 (1990-05-01), None
patent: 0 533 267 (1992-09-01), None
patent: 1560271 (1980-02-01), None
patent: 1 560 271 (1980-02-01), None
patent: 2 027 703 (1980-02-01), None
patent: 6510107 (1966-02-01), None
patent: WO89/05799 (1989-06-01), None
patent: 91/09594 (1991-07-01), None
patent: 9109594 (1991-07-01), None
patent: 92/18475 (1992-10-01), None
patent: 93/00313 (1993-01-01), None
patent: 9300313 (1993-01-01), None
patent: 9811068 (1998-03-01), None
patent: 98/11068 (1998-03-01), None
patent: 00/03713 (2000-01-01), None
patent: WO00/78728 (2000-12-01), None
Chemical Abstract DN 65:38471, also cited as NL 6510107, 1966.
U.S. Appl. No. 10/168,297, filed Nov. 20, 2002.
Joseph T. Coyle et al, Science vol. 219, 1184-1190(1983).
Grunblatt et al(PubMed Abstract 10335493).
Grunblatt et al(PubMed Abstract 10863545).
Chemical Abstract CA 132:35590. “Synthesis of piperidine analogos of 1-(3-cholrophenyl)piperazine, a well known serotonin ligand.” Radl et al., Journal of Heterocyclic Chemistry (1999), 36(4), pp. 1017-1022.
Chemical Abstract CA 116:250000. “Quantitative structure-metabolism relationship analyses of MAO-medicated toxication of 1-methyl-4-phenyl-1,2,3,5-tetrahydropyridine and analogs.” Cosimo et al., Chemical Research in Toxicology (1992), 5(3), pp. 366-375.
Carlsson et al., “Interactions Between Glutamatergic and Monoaminergic Systems within the Basal Ganglia—Implications for Schizophrenia and Parkinson's Disease”, TINS, (1990), pp. 272-276, vol. 13, No. 7, Elsevier Science Publishers Ltd., United Kingdom.
Feldman et al. (Editors), “Principles of Neuropsychopharmacology”, Chapter 17—Mind Altering Drugs, (1997), pp. 731, 762, 763, Sinauer Associates, Inc., Publishers, Sunderland, Massachusetts, USA.
Bloom et al. (Editors), “Psychopharmacology—The Fourth Generation of Progress”, Chapter 21, pp. 227, 237, Chapter 22, pp. 245, 254, Chapter 25, pp. 283, 292, Chapter 26, pp. 295-301, Chapter 66, pp. 759-760, 1725, 744-746, Chapter 68, pp. 787, 793-795, Chapter 80, pp. 921-925, 927-928, Chapter 101, pp. 1205, 1207-1209, Chapter 111, pp. 1311, 1317, 1318, 1320, Chapter 126, pp. 1479-1482, Chapter 137, pp. 1591, 1600, Chapter 138, pp. 1609-1610, 1612, (1995), Raven Press, New York, New York, USA.
Carlberg Jenny Maria
Lilja Anders Kristoffer
Rönnqvist Liselott Lilja
Sonesson Clas
Svan Ingela Marianne
A. Carlsson Research AB
Burns Doane , Swecker, Mathis LLP
Raymond Richard L.
LandOfFree
Modulators of dopamine neurotransmission does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulators of dopamine neurotransmission, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of dopamine neurotransmission will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3498539